Screening for Obstructive Sleep Apnea in Medical Patients

Obstructive Sleep Apnea Clinical Trial

Official title:

Screening for Obstructive Sleep Apnea in the General Medical Ward in Tertiary Care Centers in the Middle East

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05980936
• Other study ID #: IH.OSAScrnng.2023/2
• Status: Recruiting
• Start date: October 15, 2023
• Est. completion date: October 30, 2024

Study information

• Verified date: December 2023
• Source: Jordan Collaborating Cardiology Group
• Contact: Ayman Hammoudeh, MD, FACC
• Phone: 0096265001000
• Email: a.hammoudeh[@]istisharihospital.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences.

Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general medical wards with these symptoms will be evaluated for the possibility of having OSA.

Description:

Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is associated with adverse cardiovascular events.

Screening for OSA is recommended in men and women who have the typical symptoms, including snoring, daytime sleepiness, or abrupt awakenings with choking or gasping.

OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias, and atrial fibrillation.

Heart failure patients should also be screened for OSA. It is very important to increase the use of OSA screening especially in patients admitted to the medical floor in tertiary care hospitals. No study has evaluated this topic in the Middle East in the past.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: October 30, 2024
• Est. primary completion date: October 15, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing to sign an informed consent

• Patient is admitted to the medical ward in a tertiary hospital

Exclusion Criteria:

• Patients known to have obstructive sleep apnea.

• Patients younger than 18 years of age

Related Conditions & MeSH terms

• Apnea
• Obstructive Sleep Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Other:
• Screening for obstructive sleep apnea
Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep

Locations

Country	Name	City	State
Jordan	Ayman Hammoudeh	Amman
Jordan	Istishari Hospital	Amman

Sponsors (1)

Lead Sponsor	Collaborator
Jordan Collaborating Cardiology Group

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants who are found to have obstructive sleep apnea	Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA	From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.